Unlocking the transcriptome
Our Intelligent Transcriptome Platform integrates gene expression, clinical and multi-omic data and advanced AI algorithms to understand and predict the biological impact of diseases and therapies.
The Intelligent Transcriptome Constantly Advancing
An engine with unprecedented abilities to mine data, learn models, and intelligently identify candidate targets and multidimensional biomarkers.
A Platform Designed and Validated by World Experts in Transcriptome Analysis and Machine Learning
The Intelligent Transcriptome
Platform Overview
Input RNA-seq samples, labels, and related data
TxomeAI® performs a wide range of analysis and feature extraction
And builds a deep molecular profile with comprehensive features for each sample
DeepSea ™ provides transcriptomes, pre-trained models, and related data to add power to analyses
DiscoverAI™ automatically sifts through millions of data points to identify the most relevant features and constructs transparent, generalizable predictors for your endpoints
Targets
Biomarkers
Signatures
Unique Capabilities
Extensive experience deploying our platforms for various endpoints in drug discovery and development.
Identify new patient populations for label expansion
Determine mechanisms of action
Discover drug targets
Predict transcriptomic effect
Understand biological impact of treatments and diseases
Discover novel biomarkers and signatures
Read More About What Our Platform Can Do
Our new family of expression-based Immuno-Oncology (IO) biomarkers re-frames and extends the concept of mutational burden to exploit gene expression measurements and other -omic data, improving the analytical and clinical validity of mutational-burden biomarkers. Using a novel neoantigen-focused feature selection approach, RNA-IO is trained to focus on relevant neoantigenic mutations and discard those that do not contribute to tumor immunogenicity.